Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

687
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
687
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

428
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
428

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Retraction: Comparing calpain- and caspase-3-mediated degradation patterns in traumatic brain injury by differential proteome analysis.

The Biochemical journal·2026
Same author

Retraction Note to: Degradation of βII-Spectrin Protein by Calpain-2 and Caspase-3 Under Neurotoxic and Traumatic Brain Injury Conditions.

Molecular neurobiology·2026
Same author

Biases and consistency of different assay methods for neurological biomarkers using Quanterix single-molecule-array technology: A secondary analysis method comparison study.

NeuroMarkers·2026
Same author

Characterizing Heterogeneity in Brain Morphology in Traumatic Brain Injury Using Normative Modeling.

Neurology·2026
Same author

Blood Biomarkers for Identifying Epidural Hematoma in Patients Presenting with a Glasgow Coma Scale of 13-15: A Collaborative European Neurotrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) Study.

Journal of neurotrauma·2026
Same author

Accuracy of clinical diagnosis of behavioral variant frontotemporal dementia: A systematic review and meta-analysis.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026

Related Experiment Video

Updated: Dec 20, 2025

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

669

Biomarkers.

Stefania Mondello1, Ronald L Hayes2

  • 1Department of Neurosciences, University of Messina, Messina, Italy.

Handbook of Clinical Neurology
|February 23, 2015
PubMed
Summary
This summary is machine-generated.

Biomarkers are crucial for understanding traumatic brain injury (TBI). This review details available brain injury markers, their clinical utility, and future validation for diagnosis and treatment.

Keywords:
BiomarkersCSF diagnosisTBIbloodbrain injuryclinical practicemonitoringoutcometreatment

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Related Experiment Videos

Last Updated: Dec 20, 2025

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

669
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Area of Science:

  • Neuroscience
  • Biochemistry
  • Clinical Medicine

Background:

  • Biomarkers are essential for understanding the complex pathophysiology of traumatic brain injury (TBI).
  • Identifying distinct biomarker classes can reveal initial injury and secondary cascades.
  • Biomarkers aid in diagnosis, progression tracking, targeted therapy, and treatment monitoring for TBI.

Purpose of the Study:

  • To provide a comprehensive overview of available TBI biomarkers.
  • To characterize the potential role and applications of these markers in clinical practice.
  • To discuss recent guideline inclusions and future validation perspectives for brain damage biomarkers.

Main Methods:

  • Review of existing literature on TBI biomarkers.
  • Analysis of biomarker classes reflecting core pathologic mechanisms.
  • Discussion of analytical validity, clinical utility, and regulatory standards.

Main Results:

  • Significant efforts have been made to identify novel TBI biomarkers over the past 25 years.
  • The clinical utility of brain injury markers has been debated due to inconsistent standards and evidence.
  • Recent diagnostic guidelines have begun to include brain damage biomarkers.

Conclusions:

  • Biomarkers are vital for improving TBI diagnosis, monitoring, and therapeutic strategies.
  • Robust validation of analytical validity and clinical utility is crucial for widespread adoption.
  • Future research should focus on establishing reliable evidence for biomarker use in TBI management.